ENDPOINTS NEWS1d
Avice­da aims to raise $200M; Ner­viano gets back rights to PARP1 in­hibitor
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
MaaT Pharma eyes Phase II after early success in ALS microbiome trial
The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.
Le Lézard1d
Times Higher Education's Inaugural 'Interdisciplinary Science Rankings 2025': KIIT Ranked 4th Best in India, 92nd in the World
KIIT-DU ( has secured an impressive 4th position in India in the inaugural Times Higher Education (THE) Interdisciplinary Science Rankings 2025, which recognizes universities excelling in ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...
Le Lézard6d
ActivTrak Ranked No. 468 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500tm
ActivTrak today announced it is No. 468 on the Deloitte Technology Fast 500tm, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech ...